Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Foeldvari

Showing results (131-140 of 174) with videos related to

Pageof 18
Sort By:
Expert Review of Clinical Immunology|May 5, 2026
What is the best way to plan a 12-months clinical drug trial in JIA associated uveitisIvan Foeldvari, Ameenat Solebo, Sheila T Angeles-Han, et al.
Annals of the Rheumatic Diseases|August 12, 2022
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trialHermine I Brunner, Ivan Foeldvari, Ekaterina Alexeeva, et al.
Arthritis Research & Therapy|October 25, 2011
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical featuresRudolf Mierau, Pia Moinzadeh, Gabriela Riemekasten, et al.
Journal of Scleroderma and Related Disorders|March 26, 2019
An Interim Report of the Scleroderma Clinical Trials Consortium Working GroupsMurray Baron, Bashar Kahaleh, Elana J Bernstein, et al.
Annals of the Rheumatic Diseases|March 30, 2018
Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiativeTamas Constantin, Ivan Foeldvari, Jordi Anton, et al.
Arthritis Research & Therapy|May 25, 2019
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trialIvan Foeldvari, Tamàs Constantin, Jelena Vojinović, et al.
Annals of the Rheumatic Diseases|May 23, 2013
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER studyGerd Horneff, Ruben Burgos-Vargas, Tamas Constantin, et al.
Expert Review of Clinical Immunology|June 5, 2026
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposiumIvan Foeldvari, Kathryn S Torok, Jens Klotsche, et al.
Arthritis and Rheumatism|November 30, 2006
Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international databaseGiorgia Martini, Ivan Foeldvari, Ricardo Russo, et al.
Arthritis Care & Research|August 18, 2019
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim ResultsHermine I Brunner, Kabita Nanda, Mary Toth, et al.
Pageof 18

Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Expert Review of Clinical Immunology|May 5, 2026
What is the best way to plan a 12-months clinical drug trial in JIA associated uveitisIvan Foeldvari, Ameenat Solebo, Sheila T Angeles-Han, et al.
Annals of the Rheumatic Diseases|August 12, 2022
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trialHermine I Brunner, Ivan Foeldvari, Ekaterina Alexeeva, et al.
Arthritis Research & Therapy|October 25, 2011
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical featuresRudolf Mierau, Pia Moinzadeh, Gabriela Riemekasten, et al.
Journal of Scleroderma and Related Disorders|March 26, 2019
An Interim Report of the Scleroderma Clinical Trials Consortium Working GroupsMurray Baron, Bashar Kahaleh, Elana J Bernstein, et al.
Annals of the Rheumatic Diseases|March 30, 2018
Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiativeTamas Constantin, Ivan Foeldvari, Jordi Anton, et al.
Arthritis Research & Therapy|May 25, 2019
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trialIvan Foeldvari, Tamàs Constantin, Jelena Vojinović, et al.
Annals of the Rheumatic Diseases|May 23, 2013
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER studyGerd Horneff, Ruben Burgos-Vargas, Tamas Constantin, et al.
Expert Review of Clinical Immunology|June 5, 2026
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposiumIvan Foeldvari, Kathryn S Torok, Jens Klotsche, et al.
Arthritis and Rheumatism|November 30, 2006
Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international databaseGiorgia Martini, Ivan Foeldvari, Ricardo Russo, et al.
Arthritis Care & Research|August 18, 2019
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim ResultsHermine I Brunner, Kabita Nanda, Mary Toth, et al.
Pageof 18